Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytomegalovirus pp65-specific cytotoxic T lymphocytes (University of Louisville)
- Development stage
- Phase 2
- Lead developer
- University of Louisville
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytomegalovirus pp65-specific cytotoxic T lymphocytes is an adoptive cell therapy developed by the University of Louisville for the treatment of cytomegalovirus (CMV) infections in immunocompromised patients. The therapy involves the infusion of donor-derived T cells that have been specifically activated and expanded to recognize the pp65 tegument protein, a dominant antigen of CMV. This approach aims to restore the recipient's cellular immune response against the virus, particularly in allogeneic stem cell transplant recipients who suffer from persistent or drug-refractory CMV infections. By targeting pp65-expressing cells, these CTLs facilitate the direct lysis of infected cells and help control viral replication without the toxicities associated with systemic antiviral drugs.
- Other names
- CMV pp65-specific CTLsCMV-specific cytotoxic T lymphocytescytomegalovirus pp65-specific cytotoxic T lymphocytes
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on cytomegalovirus pp65-specific cytotoxic T lymphocytes (University of Louisville).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytomegalovirus pp65-specific cytotoxic T lymphocytes (University of Louisville).